EPO (human):Fc (human) (rec.) (non-lytic)

CHF 480.00
In stock
CHI-HF-220EPO-C05050 µgCHF 480.00
 
More Information
Product Details
Synonyms Erythropoietin; Epoetin
Product Type Protein
Properties
Source/Host CHO cells
Sequence The extracellular domain of human EPO (aa 30-193) is fused to the N-terminus of the Fc region of a mutant human IgG1.
Crossreactivity Human
Biological Activity Measured by the dose-dependant stimulation of human megakaryoblastic leukemia cells.
Purity ≥98% (SDS-PAGE)
Endotoxin Content <0.06EU/μg protein (LAL test; Lonza).
Reconstitution Reconstitute at 100μg/ml in sterile PBS.
Formulation Lyophilized from 0.2μm-filtered solution in PBS.
Other Product Data Non-lytic: Acts as a long lasting fusion protein which only binds to the receptor. Mutations to the complement (C1q) and FcgR I binding sites of the IgGs Fc fragment render the fusion proteins incapable of antibody directed cytotoxicity (ADCC) and complement directed cytotoxicity (CDC).

NCBI reference NP_000790.2: EPO (human)
Declaration Manufactured by Chimerigen.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Erythropoietin is the principal hormone involved in the regulation of erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells and the maintenance of a physiological level of circulating erythrocyte mass. It is a glycoprotein produced primarily by the kidney. The biological effects of EPO are mediated by the erythropoietin receptor (Epo R). Genetic variations in EPO is associated with susceptibility to microvascular complications of diabetes type 2 (MVCD2) (including diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease and diabetic neuropathy). It is used for the treatment of anemia and misused as a performance-enhancing drug in endurance athletes.
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.